Market Cap ₹176 Cr.
Stock P/E 0.0
P/B 1.9
Current Price ₹75.2
Book Value ₹ 40.1
Face Value 10
52W High ₹89.7
Dividend Yield 0%
52W Low ₹ 43.2
Aashka Hospitals Ltd offers healthcare services in Gujarat, India. Its splendid specialities services consist of invasive and non-invasive cardiology, cardiothoracic and vascular surgery neurology and neuro surgical operation, scientific and surgical gastroenterology, nephrology, urology, oncology and onco surgical procedure, clinical haematology, ache control, endoscopy, joint replacement, backbone surgery, and vital and intensive care; and specialties offerings contain internal and general medicinal drug, general surgery comprising laparoscopic surgical procedure, obstetrics and gynaecology, orthopaedics, paediatrics and neonatology, otorhinolaryngology, ophthalmology, psychiatry, dermatology and venereology, pulmonology, anaesthesiology, breathing medicine and dental science. The business enterprise additionally provides aid offerings, which include pathology, radiology, pharmacy, health checkup, dormitory, physiotherapy and rehabilitation, dietary counselling, cafeteria, ambulance offerings, important sterile save department, scientific statistics branch, emergency offerings, and scientific recommendation and consultation. Aashka Hospitals Ltd incorporated in 2012 and is primarily based in Gandhinagar, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 28 | 27 | 41 | 40 | 19 | |
| Other Income | 0 | 0 | 0 | 0 | 3 | |
| Total Income | 28 | 27 | 41 | 40 | 22 | |
| Total Expenditure | 18 | 19 | 31 | 31 | 19 | |
| Operating Profit | 10 | 9 | 10 | 9 | 3 | |
| Interest | 6 | 5 | 3 | 3 | 3 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 4 | 3 | -3 | |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | |
| Profit After Tax | 1 | 1 | 4 | 2 | -3 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 1 | 4 | 2 | -3 | |
| Adjusted Earnings Per Share | 0 | 0 | 2.3 | 1 | -1.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -53% | -11% | 0% | 0% |
| Operating Profit CAGR | -67% | -31% | 0% | 0% |
| PAT CAGR | -250% | NAN% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 47% | NA% | NA% | NA% |
| ROE Average | -3% | 5% | 6% | 6% |
| ROCE Average | 0% | 7% | 9% | 9% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Shareholder's Funds | 15 | 24 | 29 | 97 | 94 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 25 | 25 | 20 | 17 | 16 |
| Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 1 |
| Total Current Liabilities | 13 | 10 | 15 | 15 | 17 |
| Total Liabilities | 54 | 60 | 65 | 129 | 128 |
| Fixed Assets | 46 | 44 | 49 | 48 | 45 |
| Other Non-Current Assets | 0 | 0 | 2 | 68 | 69 |
| Total Current Assets | 7 | 16 | 14 | 12 | 14 |
| Total Assets | 54 | 60 | 65 | 129 | 128 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 4 | 3 | 1 |
| Cash Flow from Operating Activities | 10 | -1 | 15 | -63 | 4 |
| Cash Flow from Investing Activities | -0 | -0 | -8 | -2 | -0 |
| Cash Flow from Financing Activities | -9 | 4 | -8 | 63 | -2 |
| Net Cash Inflow / Outflow | 1 | 3 | -1 | -2 | 2 |
| Closing Cash & Cash Equivalent | 1 | 4 | 3 | 1 | 3 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 2.29 | 1.01 | -1.1 |
| CEPS(Rs) | 2.27 | 2.2 | 3.73 | 2.25 | 0.16 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 0 | 16.25 | 41.32 | 40.19 |
| Core EBITDA Margin(%) | 34.38 | 31.58 | 24.49 | 21.57 | 1.76 |
| EBIT Margin(%) | 25.41 | 22.26 | 18.09 | 14.59 | 2.75 |
| Pre Tax Margin(%) | 4.93 | 5.06 | 10.11 | 7.15 | -13.56 |
| PAT Margin (%) | 4.93 | 5.06 | 10.11 | 5.95 | -13.56 |
| Cash Profit Margin (%) | 14.11 | 14.47 | 16.52 | 13.25 | 1.93 |
| ROA(%) | 2.52 | 2.42 | 6.58 | 2.44 | -2 |
| ROE(%) | 8.87 | 6.97 | 15.4 | 3.76 | -2.7 |
| ROCE(%) | 14.54 | 11.72 | 13.12 | 6.38 | 0.42 |
| Receivable days | 45.64 | 68.43 | 63.09 | 69.52 | 141.38 |
| Inventory Days | 6.13 | 7.37 | 5.28 | 5 | 9.11 |
| Payable days | 296.79 | 262.18 | 186.97 | 187.28 | 295.04 |
| PER(x) | 0 | 0 | 0 | 49.5 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 1.21 | 1.05 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.76 | 1.63 | 1.06 | 3.63 | 6.58 |
| EV/Core EBITDA(x) | 5.09 | 5.16 | 4.31 | 16.58 | 36.08 |
| Net Sales Growth(%) | 0 | -1.58 | 49.44 | -2.35 | -52.32 |
| EBIT Growth(%) | 0 | -13.77 | 21.46 | -21.22 | -91 |
| PAT Growth(%) | 0 | 1.2 | 198.3 | -42.51 | -208.62 |
| EPS Growth(%) | 0 | 0 | 196.74 | -55.71 | -208.61 |
| Debt/Equity(x) | 2.15 | 1.28 | 0.95 | 0.29 | 0.31 |
| Current Ratio(x) | 0.57 | 1.59 | 0.91 | 0.82 | 0.8 |
| Quick Ratio(x) | 0.53 | 1.53 | 0.87 | 0.79 | 0.78 |
| Interest Cover(x) | 1.24 | 1.29 | 2.27 | 1.96 | 0.17 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.24 | 0.3 |
| # | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Promoter | 61.28 | 61.28 | 61.28 | 61.28 | 61.28 | 61.28 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 38.72 | 38.72 | 38.72 | 38.72 | 38.72 | 38.72 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Promoter | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.34 | 2.34 | 2.34 | 2.34 | 2.34 | 2.34 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
